Navigation Links
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Date:4/20/2012

a range of blood related cancers," stated James A. Bianco, M.D., CEO of CTI.

Conference Call InformationOn Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time, members of CTI's management team will host a conference call to discuss CTI's 2012 first quarter financial results.

Conference Call Numbers
Friday, April 20, 2012
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-800-762-8779 (US Participants)
1-480-629-9645 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern Time:
1-800-406-7325 (US Participants)
1-303-590-3030 (International)
Passcode: 4533723#

Live audio webcast at www.celltherapeutics.com will be archived for post-call listening approximately two hours after call ends.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of CTI's drug candidates include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Pixuvri in particular, including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory aggressive B-cell NHL and/or other tumors as determined by the U.S. Food and Drug Administration (the "FDA") and/or the EMA, that Pixuvri may not be the fi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industryā€¯ is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... 30, 2014 Rancho BioSciences , ... have manually curated public data source TCGA ... the data is now available for other oncology ... public and internal data sources for their Pharma, Government ... of the data that becomes more easily accessible. ...
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... London, July 20 There has been a recent upsurge ... space. While the economic downturn and related credit crunch has had ... which has including four mega M&As in the first half of ... ) , , "The real intention ...
... , ... has added to its portfolio of topical hormonal modulators with the acquisition of a ... systemic activity and will be developed for skin and hair disorders associated with increased ... ...
... , SAN FRANCISCO, July 17 VIA ... focused on the development of compounds for the treatment of ... Staff Determination letter, dated July 15, 2009, from the NASDAQ ... with the minimum $2,500,000 stockholders, equity requirement for continued listing, ...
Cached Biology Technology:Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities 2Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens 2Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4
(Date:10/30/2014)... is available in German . ... prompt our fellow humans to behave socially? This is ... in game theory. Previous studies assumed that it is ... scientists from the Max Planck Institute for Evolutionary Biology ... an influence on the cooperative behaviour of others. However, ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus Technologies, ... justice technology solutions for public safety, investigation, ... has deployed exciting enhancements to its THREADS™ ... to provide actionable intelligence and focused leads ... to drive technological innovation through identifying and ...
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... Capitol Hill, experts discussed how federally funded university research ... hearing, "Fueling Local Economies: Research, Innovation and Jobs," was ... by Rep. Carolyn Maloney (D-NY). Expert witnesses focused ... Samuel Stanley, president of Stony Brook University; Zachary Shulman, ...
... will present seven societal awards to distinguished ecologists at ... Pittsburgh. The meeting, which has the theme "Global Warming: ... future," draws a critical combination of more than 3,000 ... and consequences of global warming and to discuss the ...
... years as an herbal remedy to prevent or treat colds, ... medicines in North America. However, in spite of its popularity, ... immune system are conflicting. Now researchers from ... investigating the possibility that Echinacea has other potentially more important ...
Cached Biology News:NY state the focus of Congressional hearing on how research and innovation fuel local economies 2NY state the focus of Congressional hearing on how research and innovation fuel local economies 3Ecological Society of America announces 2010 award recipients 2Ecological Society of America announces 2010 award recipients 3Ecological Society of America announces 2010 award recipients 4
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Mouse monoclonal antibody to Lats2....
Biology Products: